{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=47&state=Florida",
    "query": {
      "state": "Florida",
      "city": "Orlando",
      "page": 47
    },
    "page_size": 10
  },
  "pagination": {
    "page": 47,
    "page_size": 10,
    "total_count": 6859,
    "total_pages": 686,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=48&state=Florida&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?city=Orlando&page=46&state=Florida&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T01:17:16.550Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00134173",
      "title": "A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Coronary Disease",
        "Coronary Arteriosclerosis",
        "Hyperlipidemia"
      ],
      "interventions": [
        {
          "name": "torcetrapib/atorvastatin",
          "type": "DRUG"
        },
        {
          "name": "atorvastatin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1100,
      "start_date": "2003-10",
      "completion_date": "2006-09",
      "has_results": false,
      "last_update_posted_date": "2007-12-10",
      "last_synced_at": "2026-11-05T01:17:16.550Z",
      "location_count": 127,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 124 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "Los Altos",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00134173"
    },
    {
      "nct_id": "NCT06077760",
      "title": "A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "Intismeran autogene",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Pembrolizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 868,
      "start_date": "2023-12-06",
      "completion_date": "2035-12-21",
      "has_results": false,
      "last_update_posted_date": "2026-09-18",
      "last_synced_at": "2026-11-05T01:17:16.550Z",
      "location_count": 68,
      "location_summary": "Anchorage, Alaska • Tucson, Arizona • Yuma, Arizona + 55 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Yuma",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06077760"
    },
    {
      "nct_id": "NCT07426380",
      "title": "A Study of Eloralintide (LY3841136) in Participants With Renal Impairment and in Participants With Normal Renal Function",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Kidney Disease",
        "Renal Insufficiency Chronic",
        "Kidney Failure, Chronic",
        "Renal Impairment",
        "Renal Insufficiency",
        "End Stage Kidney Disease"
      ],
      "interventions": [
        {
          "name": "LY3841136",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 28,
      "start_date": "2026-02-24",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-11-05T01:17:16.550Z",
      "location_count": 2,
      "location_summary": "Miami Lakes, Florida • Orlando, Florida",
      "locations": [
        {
          "city": "Miami Lakes",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07426380"
    },
    {
      "nct_id": "NCT02143973",
      "title": "Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Uremic Pruritus",
        "Pruritus"
      ],
      "interventions": [
        {
          "name": "nalbuphine HCl ER",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Trevi Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 167,
      "start_date": "2014-09",
      "completion_date": "2016-01",
      "has_results": true,
      "last_update_posted_date": "2025-05-21",
      "last_synced_at": "2026-11-05T01:17:16.550Z",
      "location_count": 35,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 29 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Pine Bluff",
          "state": "Arkansas"
        },
        {
          "city": "Azusa",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02143973"
    },
    {
      "nct_id": "NCT01793883",
      "title": "Efficacy and Safety Study of Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Adults With Influenza",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Influenza"
      ],
      "interventions": [
        {
          "name": "40 mg Laninamivir Octanoate",
          "type": "DRUG"
        },
        {
          "name": "80 mg Laninamivir Octanoate",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Biota Scientific Management Pty Ltd",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "64 Years",
        "sex": "ALL",
        "summary": "18 Years to 64 Years"
      },
      "enrollment_count": 639,
      "start_date": "2013-05",
      "completion_date": "2014-05",
      "has_results": true,
      "last_update_posted_date": "2018-05-31",
      "last_synced_at": "2026-11-05T01:17:16.550Z",
      "location_count": 70,
      "location_summary": "Scottsboro, Alabama • Camp Verde, Arizona • Chandler, Arizona + 59 more",
      "locations": [
        {
          "city": "Scottsboro",
          "state": "Alabama"
        },
        {
          "city": "Camp Verde",
          "state": "Arizona"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Harrisburg",
          "state": "Arkansas"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01793883"
    },
    {
      "nct_id": "NCT02859961",
      "title": "Study of PRO 140 SC as Single Agent Maintenance Therapy in Virally Suppressed Subjects With CCR5-tropic HIV-1 Infection",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "HIV"
      ],
      "interventions": [
        {
          "name": "PRO 140 (350 mg)",
          "type": "DRUG"
        },
        {
          "name": "PRO 140 (525 mg)",
          "type": "DRUG"
        },
        {
          "name": "PRO 140 (700 mg)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CytoDyn, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 562,
      "start_date": "2016-12-07",
      "completion_date": "2020-12-07",
      "has_results": true,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-11-05T01:17:16.550Z",
      "location_count": 12,
      "location_summary": "La Mesa, California • Palm Springs, California • San Francisco, California + 9 more",
      "locations": [
        {
          "city": "La Mesa",
          "state": "California"
        },
        {
          "city": "Palm Springs",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        },
        {
          "city": "Norwalk",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02859961"
    },
    {
      "nct_id": "NCT03796962",
      "title": "A Study to Evaluate XEN1101 as Adjunctive Therapy in Focal Epilepsy",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Focal Epilepsy"
      ],
      "interventions": [
        {
          "name": "XEN1101",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Xenon Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 325,
      "start_date": "2019-01-30",
      "completion_date": "2028-10",
      "has_results": true,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-11-05T01:17:16.550Z",
      "location_count": 54,
      "location_summary": "Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03796962"
    },
    {
      "nct_id": "NCT00433446",
      "title": "S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "CNTO 328",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 62,
      "start_date": "2007-04",
      "completion_date": "2011-07",
      "has_results": true,
      "last_update_posted_date": "2013-02-05",
      "last_synced_at": "2026-11-05T01:17:16.550Z",
      "location_count": 123,
      "location_summary": "Anniston, Alabama • Springdale, Arkansas • Berkeley, California + 77 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Springdale",
          "state": "Arkansas"
        },
        {
          "city": "Berkeley",
          "state": "California"
        },
        {
          "city": "Burlingame",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00433446"
    },
    {
      "nct_id": "NCT06082661",
      "title": "Blood Collection for COM/BSBS",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Healthy"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Central Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 5000,
      "start_date": "2022-06-23",
      "completion_date": "2027-06",
      "has_results": false,
      "last_update_posted_date": "2024-12-06",
      "last_synced_at": "2026-11-05T01:17:16.550Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06082661"
    },
    {
      "nct_id": "NCT05560269",
      "title": "Verbal Cueing vs Constraint-Led Approach for Teaching the Kettlebell Swing",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Movement Disorders",
        "Muscle Tenderness"
      ],
      "interventions": [
        {
          "name": "Verbal coaching vs. Constraint based coaching",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Central Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 66,
      "start_date": "2022-05-02",
      "completion_date": "2024-05-05",
      "has_results": false,
      "last_update_posted_date": "2024-06-07",
      "last_synced_at": "2026-11-05T01:17:16.550Z",
      "location_count": 1,
      "location_summary": "Orlando, Florida",
      "locations": [
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05560269"
    }
  ]
}